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Abstract CD95 (Fas, APO-1)-induced programmed cell death
(apoptosis) in T cell lines is accompanied by a rapid flip-flop of
phosphatidylserine (PtdSer). Externalization of this phospholipid
has been previously recognized as one of the early detectable
events of cells undergoing apoptosis. We show here that CD95
induces a rapid (detectable at time 6 15 min), strong (2.5-fold)
but transitory neosynthesis of PtdSer in the Jurkat cell line that
precedes its externalization. PtdSer decarboxylation, a mito-
chondrial specific process, was strongly inhibited by CD95
suggesting that changes in mitochondrial activity take place in
the early events of Fas-induced apoptosis and participate in the
increased PtdSer synthesis observed. In cells undergoing
apoptosis, newly synthesized PtdSer first exposed at the cell
surface was in part shed with CD95-induced plasma membrane
vesicles, a process that likely explains the transitory effect
observed.
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1. Introduction
Phosphatidylserine (PtdSer) is synthesized by the serine
base exchange enzyme system (serine-BEES) in the endoplas-
mic reticulum. This enzymatic system catalyzes a Ca2-de-
pendent exchange of the polar head group of phospholipids
(either choline or ethanolamine) by a serine [1,2]. Newly syn-
thesized PtdSer migrates either to the internal lea£et of the
plasma membrane or to the mitochondria where it is decar-
boxylated into phosphatidylethanolamine (PtdEtn).
Apoptosis is a general phenomenon that occurs in many cell
types. It is characterized by membrane blebbing and vesicu-
lation, chromosomal condensation, cleavage of DNA and
subsequent cell death [3,4]. Binding of agonistic anti-Fas anti-
body to Fas induces apoptosis in Fas-bearing cells and kills
them within hours. The mechanism used by the Fas antigen to
kill cells involves the activation of a family of caspases re-
cruited in the death-inducing signaling complex through
FADD/MORT-1 and the Fas death domain [5,6]. Since the
work of Fadok and collaborators [7] it has been clearly estab-
lished that cross linking the Fas antigen induces the £ip-£op
of PtdSer. This anionic phospholipid is located at the internal
lea£et of the plasma membrane. During the apoptotic process,
PtdSer is translocated to the outer lea£et where it is easily
detected using the annexin V-FITC binding properties [8,9].
It has been proposed that exposure of PtdSer at the cell sur-
face is used for the recognition by phagocytes of cells under-
going apoptosis [10]. In addition, it has been shown that
changes in mitochondrial activity (generally monitored
through modi¢cation of the mitochondrial transmembrane
potential) are one of the earlier events in the apoptotic process
[11,12].
In the present report, we have examined the e¡ect of CD95
on PtdSer metabolism and we show that CD95 induces an
early and transitory synthesis of PtdSer together with an in-
hibition of PtdSer decarboxylation. The increase of PtdSer
synthesis was detected within 15 min and thus clearly precedes
its appearance at the cell surface (detected at time s 60 min).
Newly synthesized PtdSer was partly recovered on the exter-
nal lea£et of the plasma membrane and in CD95-induced shed
vesicles.
2. Materials and methods
2.1. Cells
Jurkat cells, either the clone D we have previously described [13] or
clone JE6.1 (ATCC TIB 152), were cultured in RPMI 1640 (Gibco,
Cergy-Pontoise, France) supplemented with 5% fetal calf serum (Bio-
whitaker, Fontenay, France), 50 units/ml penicillin, 50 Wg/ml strepto-
mycin, 2 mM L-glutamine, 1 mM pyruvate.
2.2. Materials
Puri¢ed (CH-11, IgM and ZB4, IgG) and phycoerythrin-conjugated
(UB2) CD95 monoclonal antibodies were purchased from Immuno-
tech (Marseille, France). L129 mouse IgM directed against CD99 [16]
was produced in our laboratory and used as negative control. L-[3-
3H]Serine (0.74^1.48 TBq/mmol), [methyl-3H]choline chloride (2.8^3.1
TBq/mmol) and [1-3H]ethan-1-ol-amine hydrochloride (0.18^1.1 TBq/
mmol) were from Amersham, UK.
2.3. Cyto£uorimetry
Cell analysis by cyto£uorimetry was performed with a FACStar
Plus cell sorter (Becton Dickinson, Mountain View, CA, USA). Apo-
alert Annexin V apoptosis kits were from Clontech Laboratories (Palo
Alto, CA, USA); they were used exactly as described by the manu-
facturer. CD95-induced apoptosis was also studied by cyto£uorimetry
with the use of the DNA marker, Hoechst 33342 [14].
2.4. Phospholipid synthesis
Jurkat cells (2U106) were maintained in 0.5 ml of a bu¡er (pH 7.4)
containing 137 mM NaCl, 2.7 mM KCl, 2.5 mM glucose, 20 mM
HEPES, 1 mM MgCl2, 1 mM CaCl2 at 37‡C in the presence of either
4 WCi of L-[3-3H]serine, [methyl-3H]choline chloride or [1-3H]ethan-1-
ol-amine hydrochloride and e¡ectors (see concentrations in the ¢gure
legends). After an incubation period varying from 0 to 2 h the cells
were rapidly sedimented in an Eppendorf centrifuge, the supernatants
were either discarded or further analyzed after centrifugation (13 000
rpm, 15 min). The cellular phospholipids were extracted using chloro-
form/methanol according to Bligh and Dyer [15]. This two-step ex-
traction procedure allowed the determination of 3H-labeled products
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incorporated into the cells by measuring a 25-Wl sample of the chloro-
form/methanol extract. Then the addition of chloroform and water
allowed the separation of the organic and aqueous phases. The lipid
extracts (organic phases) were analyzed by thin layer chromatography
on LK6D chromatography plates (Whatman) in a solvent system
composed of chloroform/methanol/acetic acid/water (75/45/12/3). Au-
thentic phospholipid standards (Sigma) were run in parallel and de-
tected with iodide vapors. Derivatization with trinitrobenzene sulfo-
nate (TNBS) was performed exactly as previously described [16].
Radioactivity in lipid spots was determined using an automatic linear
radiochromatography analyzer, Tracemaster 20 (Berthold), equipped
with an 8-mm window and the integration software supplied by the
manufacturer.
2.5. Analysis of DNA fragmentation
Analysis of DNA fragmentation was performed by agarose gel
electrophoresis. Brie£y, pelleted cells were lysed in 0.2% Triton X-
100 in 10 mM Tris-HCl/1 mM EDTA, pH 7.5 and the cell lysates
were treated with proteinase K and RNase centrifuged at 15 000Ug
for 15 min. The ¢nal extracts were resolved by electrophoresis on
agarose gels impregnated with ethidium bromide and were visualized
under UV light.
2.6. Measurements of changes in cytosolic Ca2
The assay of cytosolic Ca2 was performed using Indo-1 (Calbio-
chem). Cells (5U106/ml) were loaded by using 5 WM Indo-1 at 37‡C in
the dark for 1 h and then washed and resuspended in medium. The
analyses were performed on a £uorescence-activated cell sorter (FAC-
Star Plus, Becton Dickinson) ¢tted with two argon lasers, one tuned
to 488 nm and the other to UV. The £uorescence intensity at 480 nm
corresponding to the free Indo-1 concentration as well as the £uores-
cence at 400 nm corresponding to the complex Ca2-Indo-1 was meas-
ured. Calculation of the ratio of £uorescence at 400 nm to £uores-
cence at 480 nm allows the evaluation of changes in cytosolic free
Ca2 concentration independently of the cell size and the intracellular
Indo-1 concentration. The £ow rate was set at 1000 cells/s and the
mean ratio of 3000 cells was noted every 30 s. Damaged cells and
debris were gated out according to the dual scatter dot plot from the
blue laser.
2.7. Measurements of membrane potential
Membrane potential was estimated by measuring the £uorescence
of Jurkat cells incubated with the carbocyanine-based probe,
DiOC5(3) (Molecular Probes, Interchim, Paris). Cells were allowed
to react with the probe in 1 ml of the appropriate medium for
15 min and then the £uorescence was analyzed by cyto£uorimetry
(FACStar Plus, Becton Dickinson). Calibration experiments were
done with Jurkat cells treated with gramicidin as previously described
[17].
3. Results
3.1. CD95 induces an early and transitory PtdSer synthesis
We ¢rst tested the ability of CD95 (CH-11, IgM) to modify
phospholipid synthesis in Jurkat cells. Dose-response curves
and kinetics of [3H]serine incorporation into PtdSer were
studied in parallel. In our ¢rst experiments, the incorporation
of [3H]serine into PtdSer was studied by introducing simulta-
neously both CD95 and [3H]serine into the cell culture. In
these conditions, it appeared that CD95 induced PtdSer syn-
thesis with an EC50 between 0.25 and 0.5 Wg/ml. The incor-
poration of [3H]serine into PtdSer was doubled when studied
at time 15 min. Increasing the incubation time in the presence
of CD95 to 60 min or 120 min resulted in a lower PtdSer
synthesis (Fig. 1A). To con¢rm this unexpected result, cells
were ¢rst incubated with CD95 for di¡erent time periods
varying from 0 to 120 min and then the incorporation of
[3H]serine into PtdSer was monitored at time 15 and 30
min. Using these experimental conditions, it appeared clearly
that CD95-induced PtdSer synthesis decreased with incuba-
tion time (Fig. 2). The CD95-induced PtdSer synthesis was
43 þ 7%, 30 þ 5% and 22 þ 8% after 30, 60 and 90 min respec-
tively. After 120 min of treatment with 0.25 Wg CD95, the
amount of PtdSer synthesized was lower than in the controls.
The early increase of PtdSer synthesis induced by CD95
was observed in the absence of changes in the total uptake
of [3H]serine by the cells (see Fig. 4). CD95 treatments longer
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Fig. 1. E¡ect of CD95 mAb (CH-11) on the incorporation of
[3H]serine into phosphatidylserine (PtdSer) in Jurkat cells. 5U106/ml
cells were incubated for di¡erent periods of time at 37‡C in the ab-
sence or presence of CD95 mAbs with 4 WCi/ml [3H]serine. Phos-
pholipids were extracted, analyzed by thin layer chromatography
and quanti¢ed with a radiochromatography scanner. A: Dose-re-
sponse curves obtained after 15 min (F), 60 min (b) or 90 min (R)
after CD95 treatment. The results are expressed in % versus control
untreated cells. B: The agonistic CD95 mAb (CH-11) (b) was com-
pared to ZB-4 (E), another CD95 mAb unable to induce apoptosis
in Jurkat cells, and to L129 (a), an irrelevant mouse IgM directed
agaisnt CD99. C: The CD95 concentration-dependent increase in
PtdSer synthesis 15 min after CD95 treatment of cells. D: The
amount of PtdSer decarboxylated to PtdEtn 15 min after treatment
of the cells with di¡erent concentrations of CD95 (CH-11). For
panels C and D, each bar corresponds to the mean value þ S.D.
from triplicate points and is representative of several experiments.
Fig. 2. E¡ect of preincubation with CD95 mAb (CH-11) on PtdSer
synthesis. Cells were left untreated (open symbols) or incubated at
time 0 with 250 ng of CD95 mAb (closed symbols) then at time 0
(F, E), 30 (b, a), 60 (R, O) and 120 min (S, P) [3H]serine was
added and PtdSer synthesis was evaluated after an additional incu-
bation time of 15 or 30 min.
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than 60 min resulted in a decreased [3H]serine uptake by the
cells as a consequence of cell depolarization (see below).
Measurements of the incorporation of [3H]choline or
[3H]ethanolamine into PtdCho or PtdEtn respectively after
15 or 30 min treatment with CD95 showed no signi¢cant
modi¢cations (not shown). Identical results were obtained
with two Jurkat clones, J D and J E6.1 that di¡er by the
presence (J D) or absence (J E6.1) of the tyrosine protein
kinase p72syk [18].
3.2. PtdSer synthesis is generated only by agonistic mAbs
The enhancing e¡ect of CD95 on PtdSer synthesis was fur-
ther con¢rmed by comparing the e¡ects of two CD95 mAbs
CH-11 (IgM) and ZB-4 (IgG1), the ¢rst capable of inducing
apoptosis while the second is not. Fig. 1B shows that only
CH-11 is able to markedly increase Ptdser synthesis.
3.3. CD95 does not modify Ca2+ movements
Since the serine base exchange enzyme is a Ca2-dependent
enzyme located in the endoplasmic reticulum and since
changes in PtdSer metabolism generally occurred in parallel
with changes in Ca2 mobilization we tested whether CD95 is
able to induce changes in [Ca2]i or to modify CD3-induced
Ca2 movements. This was not the case (Fig. 3A). In addi-
tion, the Ca2 content of the endoplasmic reticulum in control
and CD95-treated cells was assessed using ionomycin in
EGTA-containing media. As shown in Fig. 3B, no modi¢ca-
tion was found suggesting that the CD95-induced PtdSer syn-
thesis we observed was not related to changes in intracellular
Ca2.
3.4. CD95 inhibits PtdSer decarboxylation
It is well known that newly synthesized PtdSer migrates
either to the internal lea£et of the plasma membrane or to
the mitochondria where it is decarboxylated to PtdEtn. Since
early changes of mitochondrial activity occur during CD95-
induced apoptosis we examined the fate of PtdSer. Monitor-
ing the formation of PtdEtn through decarboxylation of
PtdSer indicated (Fig. 1D) that the decarboxylation process
was strongly diminished.
3.5. CD95 induces cell depolarization
In a previous paper [17] we have shown that PtdSer syn-
thesis was highly regulated by changes in the membrane po-
tential. In fact, a depolarization of the cells reduced the trans-
port of serine through the plasma membrane resulting in a
strong reduction of PtdSer synthesis. In order to see whether a
change in membrane potential occurred in CD95-treated cells
we ¢rst measured the membrane potential with the DiOC5(3)
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Fig. 5. Evaluation of CD95-induced apoptosis by cyto£uorimetry.
Cells left untreated (E) or treated with 500 ng CD95 (CH-11) (F)
were labeled either with Hoechst 33342 (top panels), annexin V-
FITC (middle panels) or propidium iodide (lower panels). Results
represent a typical experiment. Each point is the mean þ S.D. of
triplicates. When not appearent, the S.D. value was within the
point. On the right is represented the FACS analysis at 2 h for
Hoechst 33342 and annexin V-FITC and 6 h for propidium iodide.
Fig. 4. CD95 induces a late plasma membrane depolarization and a
decreased uptake of [3H]serine. Jurkat cells (A) were left untreated
(a) or treated with CD95 (0.5 Wg/ml) (b) for di¡erent periods of
time and the membrane potential was measured by cyto£uorimetry
with the DiOC5(3) probe. The bars on the left of the ¢gure show
the polarization status of the cells at time 0 and after 15 min of
treatment with 1 WM gramicidin. B: The total uptake of [3H]serine
by the cells was measured as a function of time. Each point is the
mean þ S.D. of triplicate determinations from a typical experiment.
Fig. 3. Lack of e¡ect of CD95 on Ca2 movements. Jurkat cells
loaded with Indo-1 were analyzed as described in Section 2. A:
Control cells (a) and 1 Wg/ml CD95 (CH-11)-treated cells (b).
CD95 was added at time 0 and the Indo-1 £uorescence ratio corre-
sponding to Ca2 was monitored for 5 min. Then at time 5 min,
CD3 mAb 2 Wg/ml was added and the £uorescence ratio was moni-
tored for an additional 5 min period. B: Untreated cells (E) and
cells pretreated for 15 min with 1 Wg/ml CD95 (F) were placed in
2 mM EGTA-containing medium then immediately treated with
1036 M ionomycin in order to evaluate the Ca2 content of the in-
tracellular stores. The ¢gure represents one experiment representa-
tive of several independent measurements.
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probe. As shown in Fig. 4A, CD95 caused a marked depola-
rization that started 45 min after CD95 addition. In parallel,
we measured the uptake of [3H]serine CD95-treated Jurkat
cells. We found that CD95 induced a marked decrease of
[3H]serine uptake (Fig. 4B) that was fully compatible with
the changes of membrane potential and the decreased PtdSer
synthesis observed in cells treated for times greater than 60
min.
3.6. Time course of CD95-induced apoptosis
CD95-mediated apoptosis was monitored by cyto£uorime-
try using either Hoechst 33342 or the Apoalert apoptosis kit
including labeling of cells with annexin V-FITC and propidi-
um iodide. As shown in Fig. 5, CD95 induced signi¢cant
changes in Hoechst 33342 DNA labeling within 2 h. Labeling
of cells with annexin V-FITC was clearly evidenced 1 h after
CD95 treatment while the cell permeability to propidium io-
dide remained unchanged before 2 h of treatment. Monitoring
DNA fragmentation by electrophoresis in agarose gels (not
shown) indicated that DNA fragmentation occurred 2 h after
CD95 addition. A similar timing was observed with CD95
concentrations ranging from 250 ng/ml to 2 Wg/ml (not
shown).
3.7. Newly synthesized PtdSer is translocated to the cell
surface
Since the CD95-induced rise in PtdSer synthesis occurred
before annexin V-FITC labeling we tested whether newly syn-
thesized [3H]Ptdser could be translocated to the external face
of the plasma membrane and thus could be derivatized with
trinitrobenzene sulfonate (TNBS). The amount of TNBS-de-
rivatized [3H]serine was 348 þ 62 cpm/106 CD95-treated cells
versus 42 þ 25 cpm/106 cells in controls. This indicated that
during the 1 h incubation with CD95, about 40% of the newly
synthesized PtdSer appeared at the cell surface.
3.8. PtdSer is released with membrane vesicles
We have shown above that long-term (s 2 h) treatment of
cells with CD95 resulted in an apparent decrease in PtdSer
synthesis. Since it is well known that CD95 induces the shed-
ding of membrane vesicles, we have on the one hand visual-
ized the occurrence of membrane shedding by cyto£uorimetry
(Fig. 6) and on the other hand measured the possible presence
of [3H]PtdSer in the CD95-induced vesicles obtained after
centrifugation of the supernatant of cells. As shown in Fig.
6 the CD95-induced plasma membrane vesicles obtained after
3 h of CD95 treatment clearly contained [3H]PtdSer. This fact
agrees well with the apparently decreased PtdSer synthesis
(Fig. 1AFig. 2) observed after long-term treatment (s 2 h)
with CD95.
4. Discussion
CD95-induced apoptosis involves intracellular signals trans-
duced by the death domain of Fas [19^21]. The death domain
interacts with FADD/MORT1 that couples Fas to a cascade
of ICE-like proteases named caspases [22^25]. Following cas-
pase activation, one of the earliest cellular changes described
during the apoptotic process is a reduction of the mitochon-
drial transmembrane potential [11,12,25,26]. Disruption of mi-
tochondrial transmembrane potential occurs before cells ex-
hibit nuclear DNA fragmentation and exposure of PtdSer on
the outer cell membrane lea£et. Inhibition of ICE-like pro-
teases prevents Fas-triggered disruption of mitochondrial
transmembrane potential and prevents apoptosis. Accord-
ingly, reduction of mitochondrial potential is considered the
earliest irreversible step of programmed cell death in lympho-
cytes [27^29].
In the present work, we have shown that triggering Fas
with CD95 mAbs results in very early changes in PtdSer me-
tabolism. CD95 induces an increased incorporation of
[3H]serine into PtdSer. This increased PtdSer synthesis is ac-
companied by a strong inhibition of PtdEtn formation
through decarboxylation of PtdSer. Both the increased PtdSer
and the reduction of its decarboxylation to PtdEtn were evi-
denced very early (15 min after CD95 treatment). The CD95-
induced PtdSer synthesis precedes DNA fragmentation,
Hoechst 33342 and propidium iodide labeling (all these events
were detected at 2 h) as well as the exposure of PtdSer at the
cell surface of cells (detected at 1 h) during programmed cell
death (Fig. 5).
PtdSer synthesis takes place in the endoplasmic reticulum
and results from an exchange of the polar head group of
preexisting phospholipids (either PtdCho or PtdEtn) by a ser-
ine [1,2]. The exchange of the polar head group is catalyzed by
the serine-BEES, a Ca2-dependent enzyme located in the
endoplasmic reticulum. Generally, changes in the serine-
BEES activity are correlated with changes in the Ca2 content
of the endoplasmic reticulum [13,30]. Because CD95 does not
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Fig. 6. Jurkat cells were maintained for 3 h without (controls) or
with CD95 (1 Wg/ml). A portion of the cells were analyzed by cyto-
£uorimetry (top panels) to visualize the formation of membrane
vesicles. The remaining cells were centrifuged and analyzed for their
content in newly synthesized [3H]PtdSer (left panel). The particles
shed in the incubation medium were recovered by centrifugation
and also analyzed for their content of [3H]PtdSer (right panel). The
values are the mean of triplicates from a representative experiment.
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induce changes in Ca2 homeostasis (Fig. 3), an increased
activity of the serine-BEES appeared unlikely to explain the
CD95-induced increase in the incorporation of [3H]serine into
PtdSer, since, in parallel with the increased PtdSer, we showed
a net decrease in the formation of PtdEtn through the decar-
boxylation of PtdSer. It appears likely that the arrest of the
decarboxylation process participates at least in part in the
accumulation of PtdSer. Whether disruption of the mitochon-
drial transmembrane potential caused by CD95 is the cause of
the blockade of the decarboxylation process is not known.
Nevertheless, the fact that PtdSer decarboxylation is a typical
mitochondrial process suggests strongly that the early changes
induced by CD95 in this cellular organite could be involved as
a cause for the e¡ect observed.
If a part of the PtdSer synthesized in the endoplasmic retic-
ulum is routed to the mitochondria, another part is routed to
the internal lea£et of the plasma membrane. Since the work
by Fadok and collaborators [7] it has been known that CD95
induces a transfer of PtdSer from the internal to the external
lea£et of the plasma membrane. It was thus of interest to see
whether newly synthesized PtdSer was translocated to the ex-
ternal lea£et. For this purpose, PtdSer was derivatized with
TNBS as previously described [16]. The results obtained in-
dicated that a portion (40%) of [3H]Ptdser was derivatizable
with TNBS thus translocated to the external lea£et of the
plasma membrane during the ¢rst hour following CD95 treat-
ment. Longer treatments with CD95 induced the appearance
of distinct protrusions of the plasma membrane (blebbing)
followed by the shedding of membrane vesicles and cellular
fragmentation. We have shown (Fig. 6) that membrane
vesicles released into the incubation medium contained newly
synthesized [3H]PtdSer.
We have also shown (Fig. 4) that CD95 treatment resulted
in a marked loss of membrane potential that started 45 min
after addition of the mAb and increased with time up to 120
min, resulting in a decreased uptake of [3H]serine and a con-
comitant decrease in PtdSer synthesis.
Both the blebbing and the membrane depolarization ob-
served likely explain why treatment of cells with CD95 for
times exceeding 1 h resulted in an apparent decrease of
[3H]PtdSer synthesis.
In conclusion, we have shown ¢rst that triggering the Fas
antigen on Jurkat cells induces a very rapid and transitory
increase in the incorporation of [3H]serine into PtdSer. This
increase appeared to be linked to an inhibition of PtdSer de-
carboxylation in the mitochondria. Secondly we have shown
that newly synthesized tritium-labeled PtdSer is translocated
to the external lea£et of the plasma membrane together with
cold preexisting PtdSer.
Acknowledgements: This work was supported by the Institut National
de la SanteŁ et de la Recherche MeŁdicale (INSERM) and Association
pour la Recherche contre le Cancer (ARC).
References
[1] Bjerve, K.S. (1973) Biochim. Biophys. Acta 306, 396^402.
[2] Bjerve, K.S. (1973) Biochim. Biophys. Acta 296, 549^562.
[3] Abastado, J.P. (1996) Res. Immunol. 147, 443^456.
[4] Cohen, J.J. (1993) Immunol. Today 14, 126^130.
[5] Nagata, S. (1997) Cell 88, 355^365.
[6] Kischkel, F.C., Hellbardt, S., Behrmann, I., Germer, M., Pawli-
ta, M., Krammer, P.H. and Peter, M.E. (1995) EMBO J. 14,
5579^5588.
[7] Fadok, V.A., Voelker, D.R., Campbell, P.A., Cohen, J.J., Brat-
ton, D.L. and Henson, P.M. (1992) J. Immunol. 148, 2207^2216.
[8] Koopman, G., Reutelinsperger, C.P.M., Kuijten, G.A.M., Keeh-
nen, R.M.J., Pals, S.T. and van Oers, M.H.J. (1994) Blood 84,
1415^1420.
[9] Martin, S.J., Reutelingsperger, C.P.M., McGahon, A.J., Rader,
J.A., Van Shie, R.C.A.A. and Green, D.R. (1995) J. Exp. Med.
182, 1545^1556.
[10] Verhoven, B., Schlegel, R.A. and Williamson, P. (1995) J. Exp.
Med. 182, 1597^1601.
[11] Kroemer, G., Petit, P., Zamzami, N., Vayssiere, J.L. and
Mignotte, B. (1995) FASEB J. 9, 1277^1287.
[12] Kroemer, G., Zamzami, N. and Susin, S.A. (1997) Immunol.
Today 18, 44^51.
[13] Aussel, C., Breittmayer, J.P., Pelassy, C. and Bernard, A. (1995)
J. Biol. Chem. 270, 8032^8036.
[14] Telford, W.G., King, L.E. and Fraker, P.J. (1992) Cytometry 13,
137^148.
[15] Bligh, E.G. and Dyer, W.J. (1959) Can. J. Biochem. Physiol. 37,
911^917.
[16] Aussel, C., Bernard, G., Breittmayer, J.P., Pelassy, C., Zoccola,
D. and Bernard, A. (1993) Biochemistry 32, 10096^10101.
[17] Breittmayer, J.P., Pelassy, C. and Aussel, C. (1996) J. Lipid Me-
diators Cell Signaling 13, 151^161.
[18] Chu, D.H., Spits, H., Peyron, J.F., Rowley, R.B., Bolen, J.B. and
Weiss, A. (1996) EMBO J. 15, 6251^6261.
[19] Chinnaiyan, A.M., O’Rourke, K., Tewari, M. and Dixit, V.M.
(1995) Cell 81, 505^512.
[20] Boldin, M.P., Varfolomeev, E.E., Pancer, Z., Mett, I.L., Camo-
nis, J.H. and Wallach, D. (1995) J. Biol. Chem. 270, 7795^7798.
[21] Boldin, M.P., Goncharov, T.M., Goltsev, Y.V. and Wallach, D.
(1996) Cell 85, 803^815.
[22] Enari, M., Talanian, R.V., Wong, W.W. and Nagata, S. (1996)
Nature 380, 723^726.
[23] Henkart, P.A. (1996) Immunity 4, 195^201.
[24] Muzio, M., Chinnaiyan, A.M., Kischkel, F.C., O’Rourke, K.,
Shevchenko, A., Ni, J., Gentz, R., Mann, M., Krammer, P.H.,
Peter, M.E. and Dixit, V.M. (1996) Cell 85, 817^825.
[25] Alnemri, E.S., Livingston, D.J., Nicholson, D.W., Salvesen, G.,
Thornberry, N.A., Wong, W.W. and Yuan, J. (1996) Cell 87,
171.
[26] Kroemer, G. and Martinez-A, C. (1994) Immunol. Today 15,
235^242.
[27] Castedo, M., Hirsch, T., Susin, S.A., Zamzami, N., Marchetti,
P., Macho, A. and Kroemer, G. (1996) J. Immunol. 157, 512^
521.
[28] Zamzami, N., Marchetti, P., Castedo, M., Decaudin, D., Macho,
A., Hirsch, T., Susin, S.A., Petit, P.X., Mignotte, B. and
Kroemer, G. (1995) J. Exp. Med. 182, 367^377.
[29] Zamzami, N., Marchetti, P., Castedo, M., Zanin, C., Vayssiere,
J.L., Petit, P.X. and Kroemer, G. (1995) J. Exp. Med. 181, 1661^
1672.
[30] Pelassy, C., Breittmayer, J.P. and Aussel, C. (1992) Biochem. J.
288, 785^789.
FEBS 20511 20-7-98
C. Aussel et al./FEBS Letters 431 (1998) 195^199 199
